<DOC>
	<DOCNO>NCT02948985</DOCNO>
	<brief_summary>Evaluation individual peripheral blood circulate tumor cell combine tumor marker detection efficacy chemotherapy patient advance colorectal cancer : A observational clinical trial</brief_summary>
	<brief_title>Evaluation CTCs Combined With Tumor Marker Detection Efficacy Chemotherapy mCRC</brief_title>
	<detailed_description>In 2004 , base AVF2107g clinical research , FDA approve bevacizumab first target drug treatment advance colorectal cancer [ 1 ] .So far , chemotherapy combine target agent currently first line standard patient advanced colorectal cancer . The anti-EGFR monoclonal antibody ( ( cetuximab panitumumab ) also demonstrate efficient treatment metastatic colorectal cancer . In CRYSTAL OPUS study , add cetuximab first-line chemotherapy ( CT ) improve clinical benefit patient ( pt ) KRAS wild-type ( wt ) mCRC [ 2,3 ] . FIRE-3 TAILOR prove cetuximab combine FORFIRI FOLFOX improve clinical benefit [ 4 ] . Target agent expensive , It necessary explore new evaluation criterion avoid unnecessary economic waste . RECIST ( Response Evaluation Criteria Solid Tumors ) suitable target immunotherapy . The effect chemotherapy display morphology ( tumor size reduction ) , also biological activity change tumor cell ( e.g.cystic degeneration cavity ) .PET-CT combine image molecular function morphology , PET-CT low cost -effective . The tumor marker rapid , easy repeat method , change marker evaluation response tumor individual indicator . So need sensitive effective evaluation marker . Circulating tumor cell ( CTCs ) rare cancer cell release tumor bloodstream think key role cancer metastasis . The distant metastasis lead cause death patient mCRC . CTCs method detect early tumor micrometastasis . CTCs predictive PFS OS lung cancer breast cancer . CTCs also predictive response tumor . CTCs accuracy , sensitive way imageology tumor marker predict therapy effect outcome . The anti-EGFR monoclonal antibody ( cetuximab ) target human epidermal growth factor receptor integrate treatment regimen mCRC . The EGFR expression predict marker cetuximab , patient express EGFR , ORR 10 % -20 % [ 5,6 ] .In CRYSTAL , The addition cetuximab FOLFIRI first-line therapy improve PFS patient KRASwild-type mCRC [ 2 ] . Up , know RAS wild type patient would benefit anti-EGFR therapy . [ 7 ] The CALGB/SWOG80405 confirm conclusion . Some study also find patient B-raf ( V600e ) mutation would benefit anti-EGFR therapy [ 8 ] . Taken together , need accuracy , sensitive method predict effect cetuximab . The study single arm , single-center , observational study undertaken anticipate 100 patient histologically confirm RAS B-raf wild type mCRC . These patient receive FOLFIRI±cetuximab therapy . Peripheral blood sample 10 mL collect patient CTCs analysis tumor marker every cycle D0 D8 . The CTCs sue integrated subtraction enrichment ( SET ) immunostaining-fluorescence situ hybridization ( iFISH ) platform.Tumor assessment perform every four cycle base RECIST v1.1 criterion use CT/MRI scan . If assessment inconsistent , collect 10ml peripheral blood ct DNA test , use BEAMing , analyze mutant gene . The correlation RAS status CTCs mutant gene ctDNA therapeutic response evaluate , find cut-off CTCs .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Having sign informed consent Age1875 year old Histologically confirm mCRC First metastatic , unresectable RAS Braf wild type .At least one measurable disease accord RECIST criterion CT/MRI Expected survival time≥12 week ECOG PS 01 Adequate bone marrow , hepatic , renal metabolic function Received chemotherapy CRC previously , except adjuvant chemotherapy end adjuvant chemotherapy≥9m ( contain irinotecan ) ≥9m ( contain irinotecan ) study . Surgery radiotherapy ≤30 day study . Received antiEGFR , antiVEGF signal pathway inhibitor previously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>CTCs</keyword>
	<keyword>ct DNA</keyword>
</DOC>